An interventional study of Omnipod M System and Omnipod S in Type 1 Diabetes, Type 1 Diabetes Mellitus and Diabetes (DM), sponsored by Insulet Corporation. Recruiting at 1 site in New Zealand. Open to participants aged 2 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Insulet Corporation · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Diabetes Mellitus, Type 1 by Insulet Corporation — 4 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Insulet Corporation.
Among the 14 studies in Diabetes Mellitus, Type 1 by Insulet Corporation, this one is the 6th largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2026, is one of 11 with no phase, and was the 14th registered.
3,756 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →4 of the 14 studies in Diabetes Mellitus, Type 1 by Insulet Corporation are open now, in 3 countries. Recruiting first, the newest first:
Insulet Corporation · Sites in United States
Ages 14–75
Insulet Corporation · Sites in France
Ages 2+
Insulet Corporation · Sites in United States
Ages 2+
By country, each count listing its studies:
Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 2 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 80 is above the median of 40 across 2,822 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 80 across the 11 interventional studies, 304 across the 3 observational. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Insulet Corporation is the lead sponsor of 23 studies on the registry; 5 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 8 (47%) have results posted.
5 of the studies in Diabetes Mellitus, Type 1 by Insulet Corporation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07593625Insulet CorporationEvaluating Glucose Control Using a Next-Generation AID Algorithm in Individuals With T1D | 2026-12-31 |
| NCT07579702Insulet CorporationEfficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System | 2027-02-22 |
| NCT06144554Insulet CorporationPost Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes | 2027-06 |
| NCT07039942Insulet CorporationFrench Prospective Multicentric Study in Real World | 2027-07-30 |
| NCT07317102Insulet CorporationOmnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B) | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 14 studies in Diabetes Mellitus, Type 1 by Insulet Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Feasibility study to evaluate the safety and feasibility of Omnipod automated insulin delivery algorithms in individuals with type 1 diabetes. This study will enroll up to 80 participants to have a minimum of 48 participants to initiate the use of Omnipod. The study will include hotel and outpatient evaluation periods.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Omnipod M System
Device: Omnipod S
Participants will use the Omnipod M System
Participants will use the Omnipod S System
Percentage of time <54 mg/dL
CGM percent time \<54 mg/dL compared to standard therapy
Time frame: 72-hour Omnipod M Hotel Period
Percentage of time <70 mg/dL
CGM percent time \<70 mg/dL compared to standard therapy
Time frame: 72-hour Omnipod M Hotel Period
Percentage of time >180 mg/dL
CGM percent time \>180 mg/dL compared to standard therapy
Time frame: 72-hour Omnipod M Hotel Period
Percentage of time <54 mg/dL
CGM percent time \<54 mg/dL compared to standard therapy
Time frame: 4-week Omnipod M outpatient
Percentage of time <54 mg/dL
CGM percent time \<54 mg/dL compared to initial data collection phase
Time frame: Final 3 weeks of Omnipod S outpatient
Percentage of time <70 mg/dL
CGM percent time \<70 mg/dL compared to standard therapy
Time frame: 4-week Omnipod M outpatient
Percentage of time <70 mg/dL
CGM percent time \<70 mg/dL compared to initial data collection phase
Time frame: Final 3-weeks Omnipod S outpatient
Percentage of time >180 mg/dL
CGM percent time \>180 mg/dL compared to standard therapy
Time frame: 4-week Omnipod M outpatient
Percentage of time >180 mg/dL
CGM percent time \>180 mg/dL compared to initial data collection phase
Time frame: Final 3-weeks Omnipod S outpatient
Started May 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.
Of 105 industry-sponsored interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's planned 7 months is below that.
Counting every sponsor, half of 955 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.